Financial Performance - Second quarter revenue reached $136.1 million, a 17.1% increase year-over-year (16.5% on a constant currency basis)[3, 10] - U S revenue increased by $15.0 million, or 15.7%, to $110.6 million compared to the second quarter of 2024[3] - International revenue grew by $4.8 million, or 23.3% (19.9% on a constant currency basis), reaching $25.6 million[3] - Gross profit for the second quarter was $101.5 million, compared to $86.8 million in the second quarter of 2024[4] - Adjusted EBITDA for the second quarter was $15.4 million, an increase of $7.6 million from the second quarter of 2024[5, 10] - Net loss improved by $1.8 million year-over-year, with a net loss of $6.2 million[10] Financial Guidance - Full year 2025 revenue is projected to be approximately $527 million to $533 million[6] - Full year 2025 Adjusted EBITDA is expected to be approximately $49 million to $52 million[6] - Full year 2025 adjusted loss per share is expected to be in the range of $0.34 to $0.39[6] Key Products and Developments - Growth was driven by key product lines, including the AtriClip® FLEX·Mini ™ device, the EnCompass® clamp, and the cryoSPHERE MAX ™ probe[3] - Enrollment was completed for all 6,500 patients in the LeAAPS trial[10]